Labskin Presents at the 2019 Microbiome Movement Conference
Day one of the conference saw Labskin take on centre stage. Alex Chapman, Head of Operations and Paul Ryan, Chief Business Development Officer of Labskin presented to an audience that included industry giants such as L’Oreal, Procter and Gamble, Unilever, Estee Lauder, Beyer, Kimberly-Clark and academics, start-ups and scale-ups.
The presentation described Labskins’ breakthrough cloning study which validates the following:
- Labskins ability to test multiple clinical trial and skincare products in parallel
- Labskins ability to clone skin microbiome
- Labskins ability to create a clone that is as close as possible to the original microbiome of human test subjects
- Labskins ability to reduce the need for human volunteers from clinical trials once the initial cloning stage has passed
Paul and Alex explained further during the presentation how scientists at Labskin cloned swabs of skin from the cheeks of healthy human volunteers. From these skin swabs, our scientists produced Labskin test subjects to allow for sequencing of the bacterial microbiome isolated and pooled together. The live bacteria, viruses and fungi (microbiota) were sustained on test subjects for up to 14 days in the Labskin laboratories in York, United Kingdom.
They went on to further describe how the Labskin AI virtual model aggregated and analysed the bacterial microbiome data, extracted the data from each sample and once it had eliminated all false or anomalous readings, to then provide test results within a 10% range of the initial human volunteer control skin.
Paul and Alex highlighted the major benefits to this study, showing how the Labskin AI model will allow multiple skincare products and topical drug samples to be tested on the same subject at the same time. This indicates how Labskin can substantially reduce development time, clinical error and clinical trial supervision costs for products. With new US FDA and EU regulations for the cosmetic and pharmaceutical sectors and stricter guidelines in place regarding product claims, industry must adapt quickly in order to stay competitive and be capable of driving the R&D process for new products as quickly and cost-effectively as possible.
For further information on the presentation, our products and services or our published research please contact info [@] labskin.co.uk.